FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Gray Cameron					2. Issuer Name and Ticker or Trading Symbol Cue Biopharma, Inc. [CUE]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
Gray Cameron									_				X Directo	r	10% C	wner	
					3. Date of Earliest Transaction (Month/Day/Year) 01/02/2020								Officer below)	(give title	Other below)	(specify	
21 ERIE STREET																	
						4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable				
(Street)								-	-	-		Line)				
CAMBRIDGE MA 02139											X Form filed by One Reporting Person						
												Form filed by More than One Reporting					
													Person				
(City)	(S	tate)	(Zip)														
		Tal	ole I - Non-	Deriva	tive S	ecurities	Ac	quired, D	isp	osed o	f, or Ber	neficiall	y Owned				
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)					Execution Date,			Code (Instr. 5)					nd Securities Form: Direct (D) or Indirect (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership		
								Code	,	Amount	(A) or (D)	Price	Reported Transact (Instr. 3 a	ion(s)		(Instr. 4)	
			Toblo II D	orivoti.	10 Co	ourition /	1 000	uired Die		and of	or Bono	ficially	Owned	<u> </u>			
			Table II - D (e					, options					Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution Da	ate, Transaction Code (Instr				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership (Instr. 4)	
				Cod	le V	(A)	(D)	Date Exercisable		xpiration ate	Title	Amount or Number of Shares		(Instr. 4)	(5)		
Stock Option (right to	\$16.31	01/02/2020		A		8,000 ⁽¹⁾		01/02/2021	. 01	1/02/2030	Common Stock	8,000	\$0.00	8,000	D		

Explanation of Responses:

1. Represents a stock option award granted on January 2, 2020 pursuant to the Issuer's Director Compensation Policy.

Remarks:

/s/ Cameron Gray by Mark Busch, attorney-in-fact

01/06/2020

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.